#SudeepPharmaIPO #IPO #NewFundOffer #PrimaryMarket #StockMarketIndia #PharmaIngredients #SpecialtyChemicals #NII #RetailInvestor #ListingGain #InvestSmart
Chandigarh: The Initial Public Offering (IPO) of Sudeep Pharma Limited, a technology-driven manufacturer of pharmaceutical excipients and specialty nutrition ingredients, has received an enthusiastic response from investors, achieving full subscription on its very first day of bidding.
As of the close of Day 1 (November 21, 2025), the total issue was subscribed 1.43 times, indicating robust initial investor interest. The Vadodara-based company, which operates in a high-margin, niche sector, is leveraging its global presence and strong financial metrics to attract capital.
💰 Subscription Status on Day 1 (Nov 21, 2025)
The strong performance was primarily driven by retail and Non-Institutional Investor (NII) categories:
| Investor Category | Subscription (Times) |
| Non-Institutional Investors (NII) | 3.01 times |
| Retail Individual Investors (RII) | 1.52 times |
| Qualified Institutional Buyers (QIB) (Ex-Anchor) | 0.09 times |
| Total Subscription | 1.43 times |
The strong oversubscription in the NII and Retail segments reflects confidence in the company’s fundamentals and its positioning in the expanding food, nutrition, and specialty ingredients markets, which are driven by increasing health awareness and rising disposable incomes.
✨ Grey Market Premium (GMP) Indicator
Market observers report that the unlisted shares of Sudeep Pharma are trading at a significant premium in the grey market, with the GMP hovering around ₹111 to ₹130 per share (approx. 19% over the upper price band). This positive sentiment in the unlisted market further indicates expectations of a strong debut on the bourses.
📊 IPO Details at a Glance
Sudeep Pharma is raising approximately ₹895 crore through its maiden public offer.
| Detail | Information |
| Issue Dates | November 21 – November 25, 2025 |
| Price Band | ₹563 to ₹593 per equity share |
| Total Issue Size | ₹895.00 Crore |
| Issue Type | Fresh Issue (₹95 Cr) + OFS (₹800 Cr) |
| Minimum Lot Size | 25 Shares (Min. Investment: ₹14,825) |
| Tentative Allotment Date | November 26, 2025 |
| Tentative Listing Date | November 28, 2025 |
| Listing At | BSE & NSE |
The proceeds from the Fresh Issue (₹95 crore) are primarily earmarked for Capital Expenditure to procure machinery for its production line at the Nandesari Facility I in Gujarat, which is expected to boost its capacity for high-margin specialty ingredients.
Analyst View: Long-Term Potential
The company’s robust financials, including high EBITDA margins near 40% and an impressive Return on Net Worth (RoNW) of 27.88% (FY25), have positioned it as a high-quality player.
Analysts largely recommend subscribing to the IPO for a long-term investment horizon (2-5 years). While the valuation is considered “aggressively priced” at a P/E multiple of approximately 45-48x (FY25 earnings), experts believe the company’s niche market leadership, strong global client base (including Pfizer and Danone), and clear expansion strategy justify the premium for sustained future growth.
#SudeepPharmaIPO #IPO #NewFundOffer #PrimaryMarket #StockMarketIndia #PharmaIngredients #SpecialtyChemicals #NII #RetailInvestor #ListingGain #InvestSmart
